Inclusion Criteria:  Female patients aged 18-70 years. ECOG score must be 0 or 1. Patients with clinical stage II to III new breast cancer, all diagnosed by hollow-core needle aspiration biopsy pathological histology prior to treatment and surgically resectable breast cancer with positive immunohistochemical staining (IHC) for HER2 (3+) or HER2 (2+) supplemented with fluorescence in situ hybridization technique (FISH). The presence of at least one measurable lesion according to RECIST 1.1 criteria. Exclusion of distant metastases by abdominal B-ultrasound, chest X-ray and whole-body bone scan prior to neoadjuvant chemotherapy, and for lymph nodes in the enlarged area fine needle aspiration cytology is required to clarify the presence of tumor metastases without a history of remaining malignancies. Expected survival of not less than 12 weeks. No previous treatment, including chemotherapy, radiotherapy, targeted therapy, and biologic therapy. -Exclusion Criteria  Exclusion Criteria:  Female patients of childbearing age who are pregnant, breastfeeding, or unwilling to use effective contraception throughout the trial period. Patients with combined severe cardiac, hepatic, renal, or endocrine system diseases and with expected survival of < 2 years for the above diseases. Inability to swallow, intestinal obstruction, the presence of other factors affecting drug administration and absorption or a history of allergy to this drug Karnofsky scale score below 60 Patients with metastatic breast cancer or bilateral breast cancer. Patients with inflammatory breast cancer. Those with a left ventricular ejection fraction (LVEF) <55% on echocardiography Those who are deemed by the personnel to be otherwise unsuitable for clinical trials.